Antidepressant Drugs Market

Fatpos Global has released a report titled “Antidepressant Drugs Market - Analysis of Market Size, Share & Trends for 2014 – 2020 and Forecasts to 2030” which is anticipated to reach USD 33.5 billion by 2031. According to a study by Fatpos Global, the market is anticipated to portray a CAGR of 6.16% between 2021 and 2031. According to the report, increase in occurrence of depression, upsurge in geriatric population, and arrival of novel techniques for the development of drugs with fewer side-effects boost the market. Additionally, rise in awareness regarding the disease condition and required clinical needs, and rise in number of people suffering from stress can boost the growth of the antidepressant drugs.

The market report on global Antidepressant Drugs market includes in-depth insights as:

• The estimated value of the market was USD 18.40 billion in the year 2021.
• Region wise, the market in North America, emerged as a key market for Antidepressant Drugs Market.
• Based on Depressive Disorder, Major Depressive Disorder segment emerged as a key segment in the global Antidepressant Drugs Market.
• Based on Product, Selective Serotonin Reuptake Inhibitors emerged as a key segment in the global Antidepressant Drugs Market
• Key players are likely to focus on product innovations and expansion through merger to retain their positions in developed markets.

“The market is primarily fueled by the rising cases of depression, increasing awareness about depression, and the rise of novel biologics. The sum of people falling prey to depression and related disorders is anticipated to continue to increase, as a result of improper eating habits, stressful work schedule, growing isolation from family and loved ones owing to technology, and the inability to adapt to the rapid pace, at which, the world is moving forward”, said a lead analyst at Fatpos Global.

Depression impacts a person's thoughts, behavior, feelings and sense of rational. Depression drugs function by fixing chemical imbalance such as absence of serotonin in the brain. Antidepressants assist in the treatment of depression by upholding balance of several hormones and chemicals in the brain.

Global Antidepressant Drugs Market is segmented by Depressive Disorder into Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others. Major depressive disorder is the maximum contributor toward the market growth as majority of the population are usually diagnosed with this disorder owing to increase in stress levels.

Key Players in the Market

Some of the key players operating in the global Antidepressant Drugs market are Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson &, Johnson, Pfizer Inc., Merck & Co. Inc., Sanofi, Sun, Pharmaceuticals Pvt Ltd, Alkermes, Bristol Myers Squibb Company, Teva Pharmaceutical Industries, Eli Lilly and Co., Takeda Pharmaceutical Co. Ltd, Forest laboratories, Akeda Pharmaceutical Other Prominent Players.

Get Valuable Insights into Global Antidepressant Drugs Market

In the new report, Fatpos Global thrives to present an unbiased analysis of the global Antidepressant Drugs market that covers the historical demand data as well as the forecast figures for the period, i.e., 2021-2031. The study includes compelling insights into growth that is witnessed in the market. The market is segmented by Depressive Disorder into Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others; By Product into Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others. Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and Middle East and Africa.